Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T06031 | Target Info | |||
Target Name | MAPK/ERK kinase kinase 1 (MAP3K1) | ||||
Synonyms |
Mitogenactivated protein kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase 1; MEKK1; MEKK 1; MEKK; MEK kinase 1; MAPKKK1
Click to Show/Hide
|
||||
Target Type | Clinical trial Target | ||||
Gene Name | MAP3K1 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | ERK activator kinase 1 (MEK1) | Clinical trial Target | ||||
UniProt ID | MP2K1_HUMAN | |||||
Gene Name | MAP2K1 | |||||
Synonyms |
PRKMK1; Mitogen-activated protein kinase kinase 1; MKK1; MEK 1; MAPKK 1; MAPK/ERKkinase 1; MAPK/ERK kinase 1; MAP kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 2 nM | [1] | ||
Co-Target Name | Proto-oncogene c-RAF (c-RAF) | Clinical trial Target | ||||
UniProt ID | RAF1_HUMAN | |||||
Gene Name | RAF1 | |||||
Synonyms |
cRaf; Raf-1; RAF proto-oncogene serine/threonine-protein kinase; RAF
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 12 nM | [2] | ||
Co-Target Name | ERK activator kinase 2 (MEK2) | Clinical trial Target | ||||
UniProt ID | MP2K2_HUMAN | |||||
Gene Name | MAP2K2 | |||||
Synonyms |
PRKMK2; MKK2; MEK 2; MAPKK 2; MAPK/ERK kinase 2; MAP kinase kinase 2; Dual specificity mitogenactivated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 16 nM | [3] | ||
Co-Target Name | Casein kinase II alpha (CSNK2A1) | Clinical trial Target | ||||
UniProt ID | CSK21_HUMAN | |||||
Gene Name | CSNK2A1 | |||||
Synonyms |
Protein kinase CK2; Casein kinase II subunit alpha; CK2A1; CK II alpha; CK II
Click to Show/Hide
|
|||||
Representative Drug(s) | CI-1040 | Drug Info | IC50 = 17 nM | [4] | ||
Co-Target Name | Casein kinase II (CSNK2) | Clinical trial Target | ||||
UniProt ID | CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN | |||||
Gene Name | NO-GeName | |||||
Representative Drug(s) | CI-1040 | Drug Info | EC50 = 100 nM | [4] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3031-4. | ||||
REF 2 | Pharmacophore identification of Raf-1 kinase inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2346-50. | ||||
REF 3 | 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J Med Chem. 2007 Oct 18;50(21):5090-102. | ||||
REF 4 | 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. J Med Chem. 2019 Feb 28;62(4):1817-1836. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.